Glucagon-like peptide-1 receptor agonists, aka GLP-1 drugs, were originally approved and used for treatment of Type 2 diabetes, with the first product debuting in 2005
For this reason, glutathione levels in the thyroid gland should be a top priority for all patients with Hashimotos
The Fasti Praenestini marks the day as feriae Iovis , as does Macrobius
(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority
Arterioscl Throm Vas
While its a functional disorder without structural damage, BPC-157 may provide symptom relief by: Modulating nitric oxide and serotonin activity Reducing visceral pain and inflammation Normalizing motility through enteric nervous system regulation BPC-157s neural and anti-inflammatory support makes it a candidate for addressing both the gut-brain axis and local irritation in IBS patients
